Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 10/20 | 1.00 |
| ▸ | MCHR2 | Q969V1 | 2/20 | 0.69 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6070018 | 0.93 | MCHR1 (0.87) | MCHR1MCHR2EPHX2ALDH1A1 | |
| SCHEMBL6069326 | 0.90 | MCHR1 (0.82) | MCHR1MCHR2OPRK1 | |
| SCHEMBL6069463 | 0.90 | MCHR1 (0.81) | MCHR1MCHR2EPHX2KDM4EALDH1A1 | |
| SCHEMBL6070315 | 0.89 | MCHR1 (0.81) | MCHR1MCHR2SMN1; SMN2OPRK1 | |
| SCHEMBL6069834 | 0.87 | MCHR1 (0.77) | MCHR1MCHR2SMN1; SMN2 | |
| SCHEMBL6070033 | 0.87 | MCHR1 (0.77) | MCHR1MCHR2OPRK1 | |
| SCHEMBL6069561 | 0.87 | MCHR1 (0.77) | MCHR1MCHR2 | |
| SCHEMBL6070500 | 0.86 | MCHR1 (0.75) | MCHR1MCHR2KDM4E | |
| SCHEMBL6069427 | 0.85 | MCHR1 (0.74) | MCHR1MCHR2 | |
| SCHEMBL6069170 | 0.83 | MCHR1 (0.72) | MCHR1MCHR2HTTEPHX2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071182-B2 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | ABBOTT LABORATORIES (US) | 2006-07-04 | — | — | US | claimed |
| US-20050277638-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | ABBVIE INC. | 2005-12-15 | — | — | US | claimed |
| US-20050137243-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | claimed |
| US-7071182-B2 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | ABBOTT LABORATORIES (US) | 2006-07-04 | — | — | US | disclosed |
| US-20050277638-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | ABBVIE INC. | 2005-12-15 | — | — | US | disclosed |
| US-20050137243-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137243-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | MCHR1, MCHR2, MC1R | MCHR1 1/4885MCHR2 2/4885HTT 81/4885 |
| US-20050277638-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | MCHR1, MCHR2, MC1R | MCHR1 1/4885MCHR2 2/4885HTT 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.